FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220803731> ?p ?o ?g. }

• W4220803731 endingPage "21" @default.
• W4220803731 startingPage "P4" @default.
• W4220803731 abstract "Abstract Background: Tubulointerstitial nephritis antigen-like 1 (Tinagl1) is reported to inhibit integrin and epidermal growth factor receptor (EGFR) and suppress tumor metastasis and growth in breast cancer. We investigated the association between Tinagl1 mRNA expression and clinicopathological factors and prognosis of breast cancer patients with long-term follow-up. The median follow-up period was 12.0 years. Materials and Methods: A total of 599 consecutive primary invasive breast cancer patients with available tissue from surgery in our hospital from 1992 to 2008 were included in this study. We examined the association between Tinagl1 mRNA expression and prognostic and clinicopathological factors using the TaqMan real-time PCR system. Statistical analysis was performed using the Kaplan-Meier method and the Cox proportional hazards model. Results: High expression of Tinagl1 mRNA was associated with significantly better disease-free survival (DFS) and overall survival (OS) than low expression (P=0.003 and P=0.01, respectively). In estrogen receptor (ER)-positive patients, DFS and OS were also better in the high Tinagl1 mRNA expression group (P=0.01 and P=0.03, respectively). However, there was no significant difference in DFS and OS in triple-negative breast cancer. Low Tinagl1 mRNA expression was positively associated with higher tumor grade. Multivariate analysis showed that low Tinagl1 mRNA expression, together with lymph node positivity, was an independent poor prognostic factor in DFS (HR 1.48; 95% CI 1.06-2.05, P=0.02). Conclusions: Our findings suggest that Tinagl1 has a role in the metastasis of breast cancer, and that its expression could be a promising candidate biomarker of prognosis in breast cancer patients. Variablesn(%)DSF Univariate P valueDFS Multivariate P valueHR (95% CI)Nodal status590Negative349 (59.2)1Positive241 (40.8)&lt;0.0001&lt;0.00013.16(2.25-4.45)Tinagl1 mRNA expression599High300 (50.1)1Low299 (49.9)0.0030.021.48(1.06-2.05) Citation Format: Akiko Kato, Naoto Kondo, Yumi Wanifuchi-Endo, Takashi Fujita, Tomoko Asano, Tomoka Hisada, Yasuaki Uemoto, Mitsuo Terada, Tatsuya Toyama. High Tinagl1 expression is a marker of good prognosis in breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-21." @default.
• W4220803731 created "2022-04-03" @default.
• W4220803731 creator A5003096253 @default.
• W4220803731 creator A5011041663 @default.
• W4220803731 creator A5015157621 @default.
• W4220803731 creator A5027634537 @default.
• W4220803731 creator A5034723123 @default.
• W4220803731 creator A5044442237 @default.
• W4220803731 creator A5058875319 @default.
• W4220803731 creator A5064980375 @default.
• W4220803731 creator A5081433438 @default.
• W4220803731 date "2022-02-15" @default.
• W4220803731 modified "2023-10-05" @default.
• W4220803731 title "Abstract P4-07-21: High <i>Tinagl1</i> expression is a marker of good prognosis in breast cancer" @default.
• W4220803731 doi "https://doi.org/10.1158/1538-7445.sabcs21-p4-07-21" @default.
• W4220803731 hasPublicationYear "2022" @default.
• W4220803731 type Work @default.
• W4220803731 citedByCount "0" @default.
• W4220803731 crossrefType "journal-article" @default.
• W4220803731 hasAuthorship W4220803731A5003096253 @default.
• W4220803731 hasAuthorship W4220803731A5011041663 @default.
• W4220803731 hasAuthorship W4220803731A5015157621 @default.
• W4220803731 hasAuthorship W4220803731A5027634537 @default.
• W4220803731 hasAuthorship W4220803731A5034723123 @default.
• W4220803731 hasAuthorship W4220803731A5044442237 @default.
• W4220803731 hasAuthorship W4220803731A5058875319 @default.
• W4220803731 hasAuthorship W4220803731A5064980375 @default.
• W4220803731 hasAuthorship W4220803731A5081433438 @default.
• W4220803731 hasConcept C121608353 @default.
• W4220803731 hasConcept C126322002 @default.
• W4220803731 hasConcept C142724271 @default.
• W4220803731 hasConcept C143998085 @default.
• W4220803731 hasConcept C2779013556 @default.
• W4220803731 hasConcept C50382708 @default.
• W4220803731 hasConcept C530470458 @default.
• W4220803731 hasConcept C71924100 @default.
• W4220803731 hasConcept C84606932 @default.
• W4220803731 hasConceptScore W4220803731C121608353 @default.
• W4220803731 hasConceptScore W4220803731C126322002 @default.
• W4220803731 hasConceptScore W4220803731C142724271 @default.
• W4220803731 hasConceptScore W4220803731C143998085 @default.
• W4220803731 hasConceptScore W4220803731C2779013556 @default.
• W4220803731 hasConceptScore W4220803731C50382708 @default.
• W4220803731 hasConceptScore W4220803731C530470458 @default.
• W4220803731 hasConceptScore W4220803731C71924100 @default.
• W4220803731 hasConceptScore W4220803731C84606932 @default.
• W4220803731 hasIssue "4_Supplement" @default.
• W4220803731 hasLocation W42208037311 @default.
• W4220803731 hasOpenAccess W4220803731 @default.
• W4220803731 hasPrimaryLocation W42208037311 @default.
• W4220803731 hasRelatedWork W2085880972 @default.
• W4220803731 hasRelatedWork W2348152691 @default.
• W4220803731 hasRelatedWork W2369039771 @default.
• W4220803731 hasRelatedWork W2415052584 @default.
• W4220803731 hasRelatedWork W2548165902 @default.
• W4220803731 hasRelatedWork W2953241133 @default.
• W4220803731 hasRelatedWork W2954762607 @default.
• W4220803731 hasRelatedWork W317834158 @default.
• W4220803731 hasRelatedWork W3206864557 @default.
• W4220803731 hasRelatedWork W2555822460 @default.
• W4220803731 hasVolume "82" @default.
• W4220803731 isParatext "false" @default.
• W4220803731 isRetracted "false" @default.
• W4220803731 workType "article" @default.